| Name | Title | Contact Details |
|---|
Welcome to Hollywood Chrysler Jeep! Here at Hollywood Chrysler Jeep, we pride ourselves on taking a different approach to selling vehicles by getting to know each and every one of our customers so we can provide a comfortable and unique shopping atmosphere. To us, its about so much more than just making the sale, because we know how important getting a fair deal on quality transportation really is for you!
Sensiba LLP is a prominent accounting and business consulting firm based in Pleasanton, California. Recently rebranded from Sensiba San Filippo LLP, the company focuses on providing a wide range of services, including audit, tax, and accounting services, as well as business consulting and tax advisory services. With a revenue of $77.3 million and around 390 employees, Sensiba is committed to enhancing business performance for its diverse clientele. The firm has received several accolades, including recognition as a Top 100 Firm by Accounting Today and being named a Top Workplace in the USA. Sensiba is also a Certified B Corporation, reflecting its dedication to social and environmental responsibility. The company fosters a people-first culture that values empathy, diversity, and collaboration, ensuring a supportive environment for both employees and clients.
Rivian Automotive, Inc. is an American electric vehicle manufacturer founded in 2009 by Robert "RJ" Scaringe. Headquartered in Irvine, California, Rivian focuses on producing electric trucks and SUVs designed for sustainability. Its flagship models include the R1T, an all-electric pickup truck, and the R1S, an all-electric SUV, both known for their powerful electric motors and impressive performance capabilities. In addition to vehicle manufacturing, Rivian develops automotive technology, particularly in electric drivetrains and autonomous driving systems. The company is also exploring opportunities in ride-sharing and driverless car markets. Rivian has garnered significant investment from major corporations, including Amazon, which has placed large orders for electric delivery vans, and Ford Motor Company. With a strong focus on innovation and sustainability, Rivian aims to meet the growing demand for electric vehicles in both consumer and commercial markets.
For 27 years and counting, SLAM has been the most authentic brand in basketball storytelling. What started as a magazine in 1994 has now grown into a global lifestyle brand and multimedia property with 20-plus social channels, a burgeoning merchandise division and multiple franchise events annually. With over 16 million engaged followers across the globe, SLAM and its channels reach fans of the NBA, WNBA, college and high school, and the worlds of fashion, sneakers, gaming and more in a unique and trusted voice. The cover of SLAM remains the Holy Grail for basketball players; if you want to play in the NBA or WNBA, you want to be on the cover of SLAM.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.